GOLDMAN SACHS GROUP INC - ALIGOS THERAPEUTICS INC ownership

ALIGOS THERAPEUTICS INC's ticker is ALGS and the CUSIP is 01626L105. A total of 61 filers reported holding ALIGOS THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
GOLDMAN SACHS GROUP INC ownership history of ALIGOS THERAPEUTICS INC
ValueSharesWeighting
Q3 2022$15,000
-87.5%
14,043
-85.8%
0.00%
Q2 2022$120,000
-57.4%
98,959
-24.6%
0.00%
Q1 2022$282,000
-19.7%
131,162
+343.3%
0.00%
Q4 2021$351,000
-4.6%
29,585
+24.6%
0.00%
Q3 2021$368,000
-52.5%
23,737
-37.5%
0.00%
Q2 2021$774,000
-18.5%
37,968
-9.1%
0.00%
Q1 2021$950,00041,7630.00%
Other shareholders
ALIGOS THERAPEUTICS INC shareholders Q2 2022
NameSharesValueWeighting ↓
Versant Venture Management, LLC 2,320,381$1,733,3250.92%
TANG CAPITAL MANAGEMENT LLC 3,329,048$2,486,7990.35%
Vivo Capital, LLC 3,547,030$2,649,6310.29%
Pivotal bioVenture Partners Investment Advisor LLC 743,215$555,1820.22%
Newtyn Management, LLC 920,000$687,2400.17%
SILVERARC CAPITAL MANAGEMENT, LLC 631,887$472,0200.14%
EcoR1 Capital, LLC 3,948,360$2,949,4250.10%
HHLR ADVISORS, LTD. 2,309,764$1,725,3940.04%
Baker Brothers Advisors 2,076,400$1,551,0710.01%
HARBOURVEST PARTNERS LLC 18,783$14,0310.01%
View complete list of ALIGOS THERAPEUTICS INC shareholders